JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
- Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading [...] Read more »
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting – Key SABRE Update Also Expected
JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month.
Read more »
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology–based therapies, today [...] Read more »
Fortrea lance un studio d’innovation en IA pour galvaniser les solutions technologiques et humaines afin d’améliorer la réalisation des essais cliniques
DURHAM, État de Caroline du Nord, 28 juin 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE), un organisme de recherche sous contrat (« ORC ») de premier plan au niveau mondial, a [...] Read more »
Fortrea startet KI-Innovationsstudio, um Technologie und menschliche Lösungen zur Verbesserung der Durchführung klinischer Studien zu bündeln
DURHAM, N.C., June 28, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (CRO), gab heute die Einführung seines Innovationsstudios für künstliche Intelligenz (KI) [...] Read more »
Fortrea Lança AI Innovation Studio para Galvanizar Tecnologia e Soluções Humanas para Aprimoramento da Entrega de Ensaios Clínicos
DURHAM, N.C., June 28, 2024 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje o lançamento do seu AI Innovation Studio, [...] Read more »
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery
DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a [...] Read more »
Adalvo erhält erste Generika-Zulassung in der EU für Liraglutid-Fertigpen
SAN ĠWANN, Malta, June 17, 2024 (GLOBE NEWSWIRE) — Adalvo gibt die erfolgreiche DCP–Zulassung für Liraglutid–Fertigpens und damit die erste Generika–Zulassung in der EU bekannt.
Als [...] Read more »
Adalvo obtient la première approbation générique de l’UE pour son stylo prérempli de liraglutide
SAN ĠWANN, Malte, 17 juin 2024 (GLOBE NEWSWIRE) — Adalvo annonce l’approbation par procédure décentralisée de son stylo prérempli de liraglutide, soit la toute première approbation [...] Read more »
Adalvo obtém primeira aprovação genérica da UE para caneta pré-cheia com liraglutida
SAN ĠWANN, Malta, June 17, 2024 (GLOBE NEWSWIRE) — Adalvo anuncia a aprovação bem–sucedida do DCP para a caneta pré–cheia com liraglutida, marcando–a como a primeira aprovação [...] Read more »
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
SAN ĠWANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) — Adalvo announces the successful DCP approval for Liraglutide pre–filled pen, marking it as the first generic approval in the EU.
As a bioequivalent version of [...] Read more »
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) — Read more »
Fortrea Finaliza Transferência das Unidades Endpoint Clinical e Patient Access para a Arsenal Capital Partners
DURHAM, N.C., June 05, 2024 (GLOBE NEWSWIRE) — A Read more »